Zeneca’s Direct-to-Consumer Advertising of Nolvadex
2005 | Case No. BME2
In May 1999, the “Moon Shot” team gathered to review the results of a $54.4 million direct-to-consumer (DTC) ad campaign. Moon Shot was a cross-functional team at Zeneca Inc., a pharmaceutical, agrochemical and specialty products company. The ad campaign was to promote the use of the drug Nolvadexâ (Zeneca’s brand name for tamoxifen citrate) for use in reducing the risk of breast cancer in women at high risk, an estimated 9 million women in the United States. This case details Zeneca’s development of tamoxifen and how the company marketed the drug. The case focuses Zeneca’s Direct-To-Consumer (DTC) prescription drug advertising campaign and the issues raised by that campaign.
This material is available for download by current Stanford GSB students, faculty, and staff, as well as Stanford University alumni. For inquires, contact the Case Writing Officeopen in new window.
Available for Purchase